Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Growth in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 10,100 shares, a growth of 1,920.0% from the December 15th total of 500 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 21,600 shares, the short-interest ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Price Performance

Shares of Xenetic Biosciences stock opened at $4.08 on Tuesday. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20. The stock has a market cap of $6.29 million, a P/E ratio of -1.53 and a beta of 2.22. The stock’s 50 day simple moving average is $4.08 and its 200-day simple moving average is $3.99.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.75 million. As a group, research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.